CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD

0.3090
21.99%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0059
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.2533
Open* 0.294
1-Year Change* -72.26%
Day's Range* 0.2635 - 0.312
52 wk Range 0.05-1.75
Average Volume (10 days) 135.94K
Average Volume (3 months) 4.25M
Market Cap 3.57M
P/E Ratio -100.00K
Shares Outstanding 44.57M
Revenue 22.36M
EPS -0.18
Dividend (Yield %) N/A
Beta 0.81
Next Earnings Date May 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 18, 2023 0.3090 0.0041 1.34% 0.3049 0.3209 0.2601
Jul 17, 2023 0.2533 -0.0607 -19.33% 0.3140 0.3166 0.2491
Jul 14, 2023 0.3153 -0.0302 -8.74% 0.3455 0.3455 0.3090
Jul 13, 2023 0.3490 0.0454 14.95% 0.3036 0.3588 0.2790
Jul 12, 2023 0.3289 -0.0499 -13.17% 0.3788 0.3987 0.3153
Jul 11, 2023 0.2606 0.0114 4.57% 0.2492 0.2669 0.2490
Jul 10, 2023 0.2617 0.0227 9.50% 0.2390 0.2638 0.2390
Jul 7, 2023 0.2491 0.0257 11.50% 0.2234 0.2502 0.2234
Jul 6, 2023 0.2263 0.0046 2.07% 0.2217 0.2321 0.2213
Jul 5, 2023 0.2272 0.0080 3.65% 0.2192 0.2332 0.2192
Jul 3, 2023 0.2148 0.0006 0.28% 0.2142 0.2259 0.2142
Jun 30, 2023 0.2144 -0.0025 -1.15% 0.2169 0.2169 0.1993
Jun 29, 2023 0.2129 0.0037 1.77% 0.2092 0.2167 0.2092
Jun 28, 2023 0.2116 -0.0276 -11.54% 0.2392 0.2392 0.2092
Jun 27, 2023 0.2413 -0.0088 -3.52% 0.2501 0.2531 0.2345
Jun 26, 2023 0.2492 -0.0099 -3.82% 0.2591 0.2591 0.2491
Jun 23, 2023 0.2597 0.0051 2.00% 0.2546 0.2603 0.2492
Jun 22, 2023 0.2566 -0.0025 -0.96% 0.2591 0.2591 0.2541
Jun 21, 2023 0.2565 0.0043 1.70% 0.2522 0.2601 0.2501
Jun 20, 2023 0.2552 -0.0014 -0.55% 0.2566 0.2671 0.2516

Aridis Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3.091 1.535 1 1.022 2.757
Revenue 3.091 1.535 1 1.022 2.757
Cost of Revenue, Total
Gross Profit
Total Operating Expense 33.084 43.524 23.401 30.109 26.874
Selling/General/Admin. Expenses, Total 7.161 7.31 6.445 6.026 3.874
Research & Development 25.923 36.936 16.956 24.083 23
Operating Income -29.993 -41.989 -22.401 -29.087 -24.117
Interest Income (Expense), Net Non-Operating -0.121 -0.245 0.068 -0.594 0.38
Other, Net -0.257 0.041 1.632
Net Income Before Taxes -30.371 -42.193 -22.333 -29.681 -22.105
Net Income After Taxes -30.371 -42.193 -22.333 -29.681 -22.105
Net Income Before Extra. Items -30.371 -42.193 -22.333 -29.681 -22.105
Net Income -30.371 -42.193 -22.333 -29.681 -22.105
Total Adjustments to Net Income 0 -4.127 0 -1.357
Income Available to Common Excl. Extra. Items -30.371 -46.32 -22.333 -29.681 -23.462
Income Available to Common Incl. Extra. Items -30.371 -46.32 -22.333 -29.681 -23.462
Diluted Net Income -30.371 -46.32 -22.333 -29.681 -23.462
Diluted Weighted Average Shares 18.7773 12.2916 9.16874 8.45828 8.10729
Diluted EPS Excluding Extraordinary Items -1.61743 -3.76843 -2.43578 -3.50911 -2.89394
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 10.4716 -3.82717 -2.43578 -3.50911 -2.89394
Unusual Expense (Income) 0 -0.722
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 19.647 1.082 1.213 0.399 0.292
Revenue 19.647 1.082 1.213 0.399 0.292
Total Operating Expense 5.978 7.345 8.633 7.811 8.029
Selling/General/Admin. Expenses, Total 1.31 1.814 1.626 1.693 1.681
Research & Development 4.668 5.531 7.007 6.118 6.348
Operating Income 13.669 -6.263 -7.42 -7.412 -7.737
Interest Income (Expense), Net Non-Operating 0.003 0.027 0.146 -0.027 0.008
Other, Net -1.528 -0.58 0.887 -0.8 -0.25
Net Income Before Taxes 12.144 -6.816 -6.387 -8.239 -7.979
Net Income After Taxes 12.144 -6.816 -6.387 -8.239 -7.979
Net Income Before Extra. Items 12.144 -6.816 -6.387 -8.239 -7.979
Net Income 12.144 -6.816 -6.387 -8.239 -7.979
Total Adjustments to Net Income 0 0 0
Income Available to Common Excl. Extra. Items 12.144 -6.816 -6.387 -8.239 -7.979
Income Available to Common Incl. Extra. Items 12.144 -6.816 -6.387 -8.239 -7.979
Diluted Net Income 12.144 -6.816 -6.387 -8.239 -7.979
Diluted Weighted Average Shares 36.573 30.4149 22.0046 17.7016 17.7016
Diluted EPS Excluding Extraordinary Items 0.33205 -0.2241 -0.29026 -0.46544 -0.45075
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.33205 -0.2241 8.52609 -0.46544 1.41349
Unusual Expense (Income) 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 11.626 24.39 12.755 25.837 28.347
Cash and Short Term Investments 4.876 18.098 8.232 20.897 24.237
Cash & Equivalents 4.876 18.098 8.232 20.897 24.237
Total Receivables, Net 1.24 0.237 0.368 0.413 1.66
Accounts Receivable - Trade, Net 1 0 1.66
Prepaid Expenses 3.341 2.7 2.182 2.99 2.45
Total Assets 14.695 26.796 15.117 27.967 31.611
Property/Plant/Equipment, Total - Net 2.147 1.357 1.258 1.006 1.271
Property/Plant/Equipment, Total - Gross 4.19 2.942 2.413 1.829 1.762
Accumulated Depreciation, Total -2.043 -1.585 -1.155 -0.823 -0.491
Intangibles, Net 0.017 0.022 0.027 0.032 0.038
Other Long Term Assets, Total 0.827 0.931 0.987 0.557 0.995
Total Current Liabilities 36.898 33.348 22.44 19.331 5.297
Accounts Payable 6.089 5.24 1.886 1.755 2.331
Accrued Expenses 10.102 6.464 1.33 2.974 2.944
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 20.188 20.948 18.785 14.602 0.022
Total Liabilities 38.927 39.906 23.798 24.331 5.297
Total Long Term Debt 0 5.282 0.276 0 0
Other Liabilities, Total 2.029 1.276 1.082 5 0
Total Equity -24.232 -13.11 -8.681 3.636 26.314
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 0.003 0.002 0.001 0.001 0.001
Additional Paid-In Capital 166.38 152.183 114.42 104.404 97.401
Retained Earnings (Accumulated Deficit) -195.666 -165.295 -123.102 -100.769 -71.088
Total Liabilities & Shareholders’ Equity 14.695 26.796 15.117 27.967 31.611
Total Common Shares Outstanding 27.0335 17.7016 10.0657 8.91846 8.10476
Long Term Investments 0 0.009 0.96
Other Current Assets, Total 2.169 3.355 1.973 1.537
Note Receivable - Long Term 0.078 0.096 0.09 0.526
Current Port. of LT Debt/Capital Leases 0.519 0.696 0.439
Long Term Debt 0 5.282 0.276
Other Equity, Total 5.051
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 4.11 3.884 6.566 11.626 8.635
Cash and Short Term Investments 0.035 0.019 1.32 4.876 1.886
Cash & Equivalents 0.035 0.019 1.32 4.876 1.886
Total Receivables, Net 0.517 0.3 0.1 1.24 0.248
Prepaid Expenses 3.558 3.565 3.16 3.341 3.768
Other Current Assets, Total 0 0 1.986 2.169 2.733
Total Assets 6.534 6.482 9.434 14.695 12.12
Property/Plant/Equipment, Total - Net 1.584 1.757 1.947 2.147 2.506
Property/Plant/Equipment, Total - Gross 3.832 3.947 4.075 4.19 4.45
Accumulated Depreciation, Total -2.248 -2.19 -2.128 -2.043 -1.944
Intangibles, Net 0.013 0.014 0.015 0.017 0.018
Note Receivable - Long Term 0 0 0.078 0.078 0.078
Other Long Term Assets, Total 0.827 0.827 0.828 0.827 0.883
Total Current Liabilities 17.482 20.394 35.431 36.898 42.277
Accounts Payable 8.82 10.967 6.159 6.089 12.025
Accrued Expenses 8.267 9.024 9.958 10.102 9.02
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0.208 0.519 0.831
Other Current Liabilities, Total 0.395 0.403 19.106 20.188 20.401
Total Liabilities 18.336 21.396 37.316 38.927 47.943
Total Long Term Debt 0 0 0 0 3.499
Long Term Debt 0 3.499
Other Liabilities, Total 0.854 1.002 1.885 2.029 2.167
Total Equity -11.802 -14.914 -27.882 -24.232 -35.823
Common Stock 0.005 0.004 0.004 0.003 0.002
Additional Paid-In Capital 170.827 168.894 168.684 166.38 153.454
Retained Earnings (Accumulated Deficit) -190.421 -190.338 -202.482 -195.666 -189.279
Total Liabilities & Shareholders’ Equity 6.534 6.482 9.434 14.695 12.12
Total Common Shares Outstanding 44.574 36.0775 36.0775 27.0335 17.7016
Accounts Receivable - Trade, Net 0.417 0.2 0 1
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Other Equity, Total 7.787 6.526 5.912 5.051
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -30.371 -42.193 -22.333 -29.681 -22.105
Cash From Operating Activities -29.127 -22.936 -20.476 -8.159 -24.271
Cash From Operating Activities 0.487 0.435 0.337 0.338 0.283
Non-Cash Items 2.056 8.305 2.137 2.961 0.066
Cash Taxes Paid 0.019 0.002 0.002 0.002 0.002
Cash Interest Paid
Changes in Working Capital -1.299 10.517 -0.617 18.223 -2.515
Cash From Investing Activities -0.082 -0.53 -0.367 -0.174 -1.677
Capital Expenditures -0.082 -0.53 -0.367 -0.174 -0.677
Cash From Financing Activities 14.782 34.72 8.678 4.993 25.089
Issuance (Retirement) of Stock, Net 12.612 29.72 7.963 4.993 25.089
Issuance (Retirement) of Debt, Net 5 5 0.715
Net Change in Cash -14.427 11.254 -12.165 -3.34 -0.859
Other Investing Cash Flow Items, Total 0 -1
Financing Cash Flow Items -2.83
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -6.816 -30.371 -23.984 -15.745 -7.766
Cash From Operating Activities -4.002 -29.127 -20.57 -16.305 -10.166
Cash From Operating Activities 0.087 0.487 0.387 0.262 0.131
Non-Cash Items -0.011 2.056 2.659 1.487 0.833
Cash Taxes Paid 0.001 0.019 0.005 0.002 0
Changes in Working Capital 2.738 -1.299 0.368 -2.309 -3.364
Cash From Investing Activities 0 -0.082 -0.033 -0.033 -0.021
Capital Expenditures 0 -0.082 -0.033 -0.033 -0.021
Cash From Financing Activities 0.263 14.782 3.75 4.304 4.443
Issuance (Retirement) of Stock, Net 2.059 12.612 0 0 0
Net Change in Cash -3.739 -14.427 -16.853 -12.034 -5.744
Issuance (Retirement) of Debt, Net 0 5 5 5 5
Financing Cash Flow Items -1.796 -2.83 -1.25 -0.696 -0.557
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Cystic Fibrosis Foundation Corporation 12.8531 5168732 0 2023-04-04 HIGH
The Lind Partners, LLC Investment Advisor 7.4601 3000000 3000000 2023-03-16 LOW
AstraZeneca PLC Corporation 2.2006 884956 0 2023-07-28 LOW
HEPALINK USA, Inc. Corporation 2.1845 878456 0 2023-07-28 LOW
Truong (Vu) Individual Investor 1.8336 737353 -15000 2023-07-28 LOW
Patzer (Eric) Individual Investor 1.745 701732 -12400 2023-07-28 LOW
Roumell Asset Management, L.L.C. Investment Advisor 1.1105 446588 0 2023-06-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.5029 202247 159000 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.3557 143034 0 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.3387 136197 -388959 2023-06-30 LOW
HRT Financial LP Investment Advisor 0.1833 73723 56496 2023-06-30 HIGH
Hamilton (John F) Individual Investor 0.141 56708 49708 2023-07-28 LOW
Minot Wealth Management LLC Investment Advisor 0.1243 50000 0 2022-06-30
Windham-Bannister (Susan Richards) Individual Investor 0.0969 38987 33987 2023-07-28 HIGH
Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.0908 36533 0 2023-06-30 MED
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.0699 28104 0 2023-06-30 LOW
Cornerstone Wealth Management, LLC Investment Advisor 0.0497 20000 20000 2023-06-30 LOW
Tower Research Capital LLC Hedge Fund 0.0407 16363 14779 2023-06-30 HIGH
Wealth Architects, LLC Investment Advisor 0.035 14077 0 2023-06-30 LOW
Virtu Americas LLC Research Firm 0.0294 11809 11809 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aridis Pharmaceuticals, Inc. Company profile

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).

Industry: Bio Therapeutic Drugs

983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US

Income Statement

  • Annual
  • Quarterly

News

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

Gold Rises as Traders price-in Fed Rate Cuts

Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

13:17, 20 November 2023
Gold bars

XAU/USD Latest: Gold advances as weaker data weighs on US yields

Gold moves higher as softer economic data weighs on US yields and the dollar

13:43, 17 November 2023

People also watch

Oil - Crude

75.50 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0211%
Short position overnight fee -0.0008%
Overnight fee time 22:00 (UTC)
Spread 0.040

US100

15,947.70 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

37,475.65 Price
+1.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.62 Price
+1.470% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading